drugset / Trial / NCT03004261
CMV-CTL for the Treatment of CMV Infection After HSCT
Phase 4
Completed
5 enrolled
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China · collab
NaSingle-groupOpen-labelTreatment
Summary
Human cytomegalovirus (CMV) infection is a major cause of morbidity and mortality for recipients of allogeneic hematopoietic stem cell transplantation(HSCT). we propose to study the immunologic and virologic effects of donor derived CMV specific cytotoxic T lymphocyte (CMV-CTL) given to transplant recipients CMV antigen peptides will be used to induce the CMV antigen specific T lymphocytes derived from donor peripheral blood mononuclear cells for a period of 18\~21 days.The patients will receive CMV-CTL cells when they are sero-positive for CMV-DNA 30 days after transplant. The CMV-DNA level will be monitored weekly after transfusion.
Timeline
- Start
- 2016-11
- Primary completion
- 2021-12-31
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytomegalovirus Specific T-Lymphocytes | Cell therapy | — | Intravenous |
| Background | Foscarnet | Small molecule | — | — |
| Background | Ganciclovir | Small molecule | — | — |